PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 15, 2016Diabetes832 citationsOpen Access

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis

View Full Paper
JSJay S. SkylerGBGeorge L. BakrisEBEzio Bonifacio

Key Points

Key points are not available for this paper at this time.

Abstract

The American Diabetes Association, JDRF, the European Association for the Study of Diabetes, and the American Association of Clinical Endocrinologists convened a research symposium, "The Differentiation of Diabetes by Pathophysiology, Natural History and Prognosis" on 10-12 October 2015. International experts in genetics, immunology, metabolism, endocrinology, and systems biology discussed genetic and environmental determinants of type 1 and type 2 diabetes risk and progression, as well as complications. The participants debated how to determine appropriate therapeutic approaches based on disease pathophysiology and stage and defined remaining research gaps hindering a personalized medical approach for diabetes to drive the field to address these gaps. The authors recommend a structure for data stratification to define the phenotypes and genotypes of subtypes of diabetes that will facilitate individualized treatment.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Skyler et al. (2016) studied this question.

synapsesocial.com/papers/6a03b2f51506208190f016f0https://doi.org/10.2337/db16-0806
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Type 1 diabetes: primary antigen/peptide/register/trimolecular complex2012 · 21 citations
  2. 2No Deterioration in Glycemic Control in HNF-1α Maturity-Onset Diabetes of the Young Following Transfer From Long-Term Insulin to Sulphonylureas2003 · 128 citations
  3. 3Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.1998 · 8,417 citations
  4. 4Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors2016 · 78 citations
  5. 5Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia2011 · 60 citations